A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24 2024 - 11:30AM
Business Wire
- Trials in Progress posters detail ongoing Phase 1/2 trials
evaluating investigational Tmod™ CAR T cell therapies
for the treatment of solid tumors
- Additional poster will demonstrate impact of expanded
biomarker enrollment criteria in improving diversity in clinical
trials based on Company’s pre-screening protocol
A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy
company developing first-in-class logic-gated cell therapies to
selectively target tumor cells and protect normal cells, today
announced the acceptance of three posters for presentation at the
American Society of Clinical Oncology (ASCO) Annual Meeting May
31-June 4, 2024, in Chicago, Ill. A2 Bio will present two Trials in
Progress on its first-in-human Phase 1/2 studies EVEREST-1 and
EVEREST-2, and one poster highlighting the BASECAMP-1 master
prescreening study protocol’s impact on increasing trial
diversity.
Poster presentations on Saturday, June
1, 9:00 am – 12:00 pm CT
EVEREST-1: A seamless phase 1/2 study of A2B530, a
carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy,
in patients with solid tumors associated with CEA expression also
exhibiting human leukocyte antigen (HLA)-A*02 loss of
heterozygosity (LOH)
Session: Developmental Therapeutics - Immunotherapy
Presenting Author: Julian Molina, MD, PhD, Mayo Clinic
Abstract #: TPS2698 Poster Bd #: 162b
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin
(MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid
tumors that show MSLN expression and human leukocyte antigen
(HLA)-A*02 loss of heterozygosity (LOH)
Session: Developmental Therapeutics - Immunotherapy
Presenting Author: Salman Punekar, MD, NYU Langone
Health Abstract #: TPS2699 Poster Bd #: 163a
Improving ethnic and racial diversity in biomarker-driven
clinical trials: A proof of concept with the BASECAMP-1 master
prescreening study of patients with high-risk solid tumors with
human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity
(LOH)
Session: Care Delivery/Models of Care Presenting
Author: Caleb Smith, MD, Mayo Clinic Abstract #: 1604
Poster Bd #: 475
About EVEREST-1
EVEREST-1 (NCT05736731) is a seamless Phase 1/2 study for
A2B530, an autologous logic-gated investigational cell therapy
developed from A2 Bio’s proprietary Tmod™ platform. The Tmod
platform provides selective killing of tumor cells and protection
of normal cells via a dual-receptor design consisting of an
activator that targets tumor cells and a blocker that protects
normal cells. A2B530 consists of an activator that targets
carcinoembryonic antigen (CEA) and a blocker that targets HLA-A*02.
HLA-A*02 is lost in tumor cells and present in normal cells in the
eligible patient population. The study is recruiting patients with
lung, colorectal and pancreatic cancers.
About EVEREST-2
EVEREST-2 (NCT06051695) is a seamless Phase 1/2 study for
A2B694, an autologous logic-gated investigational cell therapy
developed from A2 Bio’s proprietary Tmod™ platform. The Tmod
platform provides selective killing of tumor cells and protection
of normal cells via a dual-receptor design consisting of an
activator that targets tumor cells and a blocker that protects
normal cells. A2B694 consists of an activator that targets
mesothelin (MSLN) and a blocker that targets HLA-A*02. HLA-A*02 is
lost in tumor cells and present in normal cells in the eligible
patient population. The study is recruiting patients with lung,
colorectal, pancreatic, ovarian and mesothelioma cancers.
About A2 Bio
A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech
company developing first-in-class logic-gated cell therapies to
address the high unmet need in cancers. A2 Bio invented the
proprietary Tmod™ cell therapy platform to tackle the fundamental
challenge in cancer treatment—the ability of cancer medicines to
distinguish between tumor and normal cells. For more information,
please visit the company’s website at www.a2bio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423654459/en/
Christy Curran Sam Brown, Inc. christycurran@sambrown.com (615)
414-8668